MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 228 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,259,998 | +193.8% | 25,840 | +252.0% | 1.36% | +140.0% |
| Q4 2022 | $2,130,725 | +51.9% | 7,341 | -66.0% | 0.57% | +42.1% |
| Q3 2022 | $1,403,000 | -8.1% | 21,590 | +1.2% | 0.40% | -29.0% |
| Q2 2022 | $1,527,000 | -23.1% | 21,336 | +5.5% | 0.56% | -3.3% |
| Q1 2022 | $1,985,000 | -18.3% | 20,230 | -29.4% | 0.58% | +8.4% |
| Q4 2021 | $2,429,000 | -3.0% | 28,670 | -8.7% | 0.54% | -15.5% |
| Q3 2021 | $2,505,000 | -29.3% | 31,393 | -13.7% | 0.63% | -18.2% |
| Q2 2021 | $3,545,000 | -23.7% | 36,393 | -8.4% | 0.78% | -28.1% |
| Q1 2021 | $4,646,000 | +222.0% | 39,721 | +206.1% | 1.08% | +191.4% |
| Q4 2020 | $1,443,000 | -33.3% | 12,976 | -28.7% | 0.37% | -35.3% |
| Q3 2020 | $2,162,000 | -61.8% | 18,211 | -63.6% | 0.57% | -64.1% |
| Q2 2020 | $5,663,000 | +182.7% | 50,000 | +66.7% | 1.60% | +71.9% |
| Q1 2020 | $2,003,000 | – | 30,000 | – | 0.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |